2. Signaling Pathways
  3. NF-κB
  4. RANKL/RANK
  5. RANKL/RANK Inhibitor

RANKL/RANK Inhibitor

RANKL/RANK Inhibitors (10):

Cat. No. Product Name Effect Purity
  • HY-N6973
    Boldine
    		Inhibitor 99.57%
    Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK signaling pathway. It can be used in rheumatoid arthritis research.
  • HY-B0012
    Pamidronic acid
    		Inhibitor 98.00%
    Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
  • HY-B0012B
    Pamidronic acid sodium
    		Inhibitor
    Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
  • HY-B0012AR
    Pamidronate disodium (Standard)
    		Inhibitor
    Pamidronate disodium (Standard) is the analytical standard of Pamidronate disodium.Pamidronate disodium (Standard), the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium (Standard) significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium (Standard) can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
  • HY-B0012A
    Pamidronate disodium
    		Inhibitor ≥98.0%
    Pamidronate disodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
  • HY-P99966
    Narlumosbart
    		Inhibitor
    Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL).
  • HY-158311
    Anti-osteoporosis agent-8
    		Inhibitor
    Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model.
  • HY-N10062
    Amakusamine
    		Inhibitor
    Amakusamine inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced formation of multinuclear osteoclasts with an IC50 value of 10.5 μM in RAW264.7 cells.
  • HY-162280
    PROTAC BTK Degrader-9
    		Inhibitor
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model.
  • HY-W438351
    1,3-Dibenzyl-5-fluorouracil
    		Inhibitor
    1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor of osteoclastogenesis. 1,3-Dibenzyl-5-fluorouracil inhibits the expression of osteoclast markers by downregulating the receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways. 1,3-Dibenzyl-5-fluorouracil can be used in the study of metabolic bone diseases.